To battle those disruptions, AbbVie, maker of three migraine treatment options ... That trio of treatments consists of Qulipta, Botox and Ubrelvy. According to a recent analysis from GlobalData ...

"Non-oral migraine medications, such as injectables and nasal ... Meanwhile, AbbVie Inc.'s Ubrelvy and Qulipta posted combined sales of $381 million. Tonix's ability to capture more market share ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any ...

For severe migraines, drugs called triptans may be prescribed, or a newer class of drugs, calcitonin gene-related peptide (CGRP) antagonists such as Nurtec (rimegepant), Ubrelvy (ubrogepant), or ...

How to Treat Premonitory Symptoms of a Migraine Attack Treatment must be individualized ... and one study found that taking ubrogepant (Ubrelvy) during the prodrome stage can prevent the attack ...

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Sales from the neuroscience portfolio increased 16% to $2.36 billion, driven by higher sales of Botox Therapeutic, depression drug Vraylar, and migraine drugs Ubrelvy and Qulipta. Neuroscience ...

Botox continues to generate billions of dollars each year. Sales of migraine drugs Ubrelvy and Qulipta are growing at double-digit percentage rates. More winners could be on the way. AbbVie's ...